Monitoring targeted drug delivery: a key cornerstone of precision medicine by György Marko-Varga & Thomas E Fehniger
MEETING ABSTRACT Open Access
Monitoring targeted drug delivery: a key
cornerstone of precision medicine
György Marko-Varga1,2*, Thomas E Fehniger1
From 2012 Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM)
Shanghai, China. 27-29 June 2012
The application of Personalized Medicine strategies of
matching specific disease genotypes and phenotypes with
specific pharmaceutical drug treatment has shown tre-
mendous efficacy in several important diseases. The most
successful example is the targeting mutations of the
epithelial growth factor receptor by small molecule
antagonists of the tyrosine kinase in non small cell lung
cancer. The expansion of this treatment paradigm into
other diseases has led to new thinking considering the
diagnosis and treatment of disease, including “Precision
Medicine”, which seeks to provide a molecular taxonomy
of disease that can be used for guiding targeted therapy in
individual patients. Today we have only a cursory under-
standing of the patterns of actual uptake of drugs or their
active metabolites at such targeted sites in the body. In the
past such studies required extrinsic labeling of the parent
drug (ie radioactivity in PET) that potentially changed the
chemical and biological properties of the drug. New tech-
nologies such as MALDI-MSI mass spectrometry have
revolutionized the label-less tracking of drugs within tar-
geted disease tissue sites [1]. A spectral image of drug dis-
tribution in biopsy tissue compartments is created by
monitoring the signal intensity of signature ion mass fin-
gerprints unique to each compound and its metabolites at
contiguous sampling windows separated by < thirty
microns. In a Proof of Principle study, we have applied
MALDI-MSI to track the uptake and distribution of an
inhaled muscarinic receptor antagonist [2], ipratropium in
the bronchial airways of COPD patients shortly after
administration. Direct measurement of the unlabeled drug
in brochial biopsies showed that the ipratropium (parent
drug ion mass, m/z 332.332, daughter ion masses m/z
166.2, and m/z 290.2) was transported and localized to
areas of airway smooth muscle that expressed the targeted
acetylcholine receptor M3, as shown by immunohisto-
chemistry performed following mass spectrometry analy-
sis. This result is the first reported co-localization of the
unlabeled drug and its targeted receptor in man. In addi-
tion to the drug position and intensity signatures it is pos-
sible to simultaneously map the patterns of thousands of
ion masses representing peptides, proteins, phospholipids,
and metabolites that characterize healthy and diseased
states. Further, the effect of drug on the relative abun-
dances and histological positions of these ion signatures
may also provide important indices of response to therapy.
Together, these catalogs will likely become an important
part of the molecular taxonomy of disease being developed
with Precision Medicine frameworks using genomic,
genetic and proteomic approaches defining the micro-
environment of disease.
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